- Home
- BCG vs BRNS Comparison
BCG vs BRNS Comparison
Compare BCG & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCG | BRNS |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 30.4M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCG | BRNS |
|---|---|---|
| Price | $1.28 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 60.8K | ★ 76.5K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.50 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $187,144,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.86 | ★ N/A |
| Revenue Growth | ★ 10.80 | N/A |
| 52 Week Low | $1.20 | $0.51 |
| 52 Week High | $3.44 | $1.83 |
Technical Indicators
Market Signals| Indicator | BCG | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 34.28 | 60.28 |
| Support Level | N/A | $0.65 |
| Resistance Level | $1.62 | $0.74 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 3.48 | 66.07 |
Price Performance
Historical ComparisonAbout BCG Binah Capital Group Inc.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.